Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
~$190B
P/E ratio
~25×
Div yield
~2.7%
Dividend / qtr
$2.52
Profit margin
~32%
Rev. growth
+10%
Revenue
~$37B
Net income (TTM)
~$12B
In plain English
Amgen is one of the original biotech giants: it grows living cells in giant stainless-steel bioreactors to make biologic medicines — bone drugs (Prolia, Evenity), the cholesterol injection Repatha, inflammation drugs (Enbrel, Tezspire) and cancer therapies. After buying Horizon Therapeutics for ~$28B it added a rare-disease franchise (Tepezza, Krystexxa), and its big swing for the future is MariTide, a once-monthly obesity shot now in Phase 3.
In simple terms
What Amgen really sells
Amgen is one of the original biotech giants: it grows living cells in giant stainless-steel bioreactors to make biologic medicines — bone drugs (Prolia, Evenity), the cholesterol injection Repatha, inflammation drugs (Enbrel, Tezspire) and cancer therapies. After buying Horizon Therapeutics for ~$28B it added a rare-disease franchise (Tepezza, Krystexxa), and its big swing for the future is MariTide, a once-monthly obesity shot now in Phase 3.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.